Myriad Genetics, Inc. beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging -0.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.33 | not reported | not reported | |
| Q1 FY26 | $-0.16 | $-0.16 | +0.0% | Beat | |
| Q4 FY25 | not reported | $0.02 | not reported | not reported | |
| Q3 FY25 | $-0.11 | $-0.13 | -18.2% | Miss | |
| Q2 FY25 | $-0.11 | $-0.06 | +45.5% | Beat | |
| Q1 FY25 | $-0.17 | $-0.14 | +17.6% | Beat | |
| Q4 FY24 | $-0.06 | $-0.09 | -50.0% | Miss | |
| Q3 FY24 | $-0.07 | $-0.06 | +14.3% | Beat | |
| Q2 FY24 | $-0.10 | $-0.10 | +0.0% | Beat | |
| Q1 FY24 | $-0.20 | $-0.14 | +30.0% | Beat | |
| Q4 FY23 | $-0.06 | $-0.07 | -16.7% | Miss | |
| Q3 FY23 | $-0.16 | $-0.17 | -6.3% | Miss |
Back to MYGN overview · MYGN holders · MYGN KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.